SCHEMBL6768704

SCHEMBL6768704

CC(O)(CS(=O)(=O)c1ccc(NC(=O)c2cccc(F)c2)cc1)C(=O)NO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2D6 P10635 1/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
AR P10275 5/20 0.47
ABCB11 O95342 1/20 0.47
ALB P02768 1/20 0.47
PGR P06401 1/20 0.47
ADRA2C P18825 1/20 0.47
GHSR Q92847 1/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
ABCC9 O60706 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764633 0.88 NPC1 (0.52) CYP2C19CYP3A4CYP2C9CYP2D6MEN1
SCHEMBL6768091 0.87 MAPT (0.53) CYP2C19CYP3A4CYP2C9CYP2D6MEN1
SCHEMBL6764893 0.87 PTGS1 (0.50) CYP2C19CYP3A4CYP2C9CYP2D6MEN1
SCHEMBL6764639 0.87 PRMT1 (0.55) CYP2C19CYP3A4CYP2C9CYP2D6MEN1
SCHEMBL6768589 0.86 AR (0.46) CYP2C19CYP3A4CYP2C9CYP2D6ALDH1A1
SCHEMBL6764878 0.85 TP53 (0.56) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6764641 0.80 MAPT (0.54) CYP2C19CYP3A4CYP2C9CYP2D6MEN1
SCHEMBL6764678 0.77 ENPP1 (0.53) CYP2C19CYP3A4CYP2C9CYP2D6MEN1
SCHEMBL6767619 0.77 CYP2C19 (0.55) CYP2C19CYP3A4CYP2C9CYP2D6MEN1
SCHEMBL6769180 0.76 GHSR (0.53) CYP2C19CYP3A4CYP2C9CYP2D6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716844-B2 ENZYME INHIBITORS; ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS PHARMACIA CORPORATION 2004-04-06 US disclosed
EP-0984959-B1 AROMATIC SULFONYL ALPHA-HYDROXY HYDROXAMIC ACID COMPOUNDS PHARMACIA CORP (US) 2003-09-24 EP disclosed
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds PHARMACIA CORPORATION 2002-11-21 US disclosed
US-6362183-B1 PROTEASE INHIBITORS; RHEUMATIC DISEASES; ANTITUMOR AGENTS G. D. SEARLE & COMPANY 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173508-A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds MMP1, MMP2, MMP3 CYP2C19 2259/4885CYP3A4 2250/4885CYP2C9 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.